title: Polymorphic variants of cytochrome P450 2B6 (CYP2B6.4-CYP2B6.9) exhibit altered rates of metabolism for bupropion and efavirenz: a charge-reversal mutation in the K139E variant (CYP2B6.8) impairs formation of a functional cytochrome p450-reductase complex.
abstract: In this study, metabolism of bupropion, efavirenz, and 7-ethoxy-4-trifluoromethylcoumarin (7-EFC) by CYP2B6 wild type (CYP2B6.1) and six polymorphic variants (CYP2B6.4 to CYP2B6.9) was investigated in a reconstituted system to gain a better understanding of the effects of the mutations on the catalytic properties of these naturally occurring variants. All six variants were successfully overexpressed in Escherichia coli, including CYP2B6.8 (the K139E variant), which previously could not be overexpressed in mammalian COS-1 cells (J Pharmacol Exp Ther 311:34-43, 2004). The steady-state turnover rates for the hydroxylation of bupropion and efavirenz and the O-deethylation of 7-EFC showed that these mutations significantly alter the catalytic activities of CYP2B6. It was found that CYP2B6.6 exhibits 4- and 27-fold increases in the K(m) values for the hydroxylation of bupropion and efavirenz, respectively, and CYP2B6.8 completely loses its ability to metabolize any of the substrates under normal turnover conditions. However, compared with CYP2B6.1, CYP2B6.8 retains 77% of its 7-EFC O-deethylase activity in the presence of tert-butyl hydroperoxide as an alternative oxidant, indicating that the heme and the active site are catalytically competent. Presteady-state measurements of the rate of electron transfer from NADPH-dependent cytochrome P450 reductase (CPR) to CYP2B6.8 using stopped-flow spectrophotometry revealed that CYP2B6.8 is incapable of accepting electrons from CPR. These observations provide conclusive evidence suggesting that the charge-reversal mutation in the K139E variant prevents CYP2B6.8 from forming a functional complex with CPR. Results from this work provide further insights to better understand the genotype-phenotype correlation regarding CYP2B6 polymorphisms and drug metabolism.
authors.affiliation: Department of Pharmacology, University of Michigan, Ann Arbor, Michigan 48109-5632, USA.
authors.forename: Haoming
authors.initials: H
authors.lastname: Zhang
authors.forename: Chitra
authors.initials: C
authors.lastname: Sridar
authors.forename: Cesar
authors.initials: C
authors.lastname: Kenaan
authors.forename: Hemali
authors.initials: H
authors.lastname: Amunugama
authors.forename: David P
authors.initials: DP
authors.lastname: Ballou
authors.forename: Paul F
authors.initials: PF
authors.lastname: Hollenberg
mesh_terms: D000480:Alkynes; D000818:Animals; D019380:Anti-HIV Agents / Q000378:metabolism*; D018687:Antidepressive Agents, Second-Generation / Q000493:pharmacokinetics*; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics* / Q000378:metabolism; D048588:Benzoxazines / Q000378:metabolism*; D016642:Bupropion / Q000378:metabolism*; D019556:COS Cells; D002384:Catalysis; D002522:Chlorocebus aethiops; D003374:Coumarins / Q000378:metabolism; D003521:Cyclopropanes; D065702:Cytochrome P-450 CYP2B6; D004579:Electron Transport; D004926:Escherichia coli / Q000378:metabolism; D005290:Ferric Compounds / Q000378:metabolism; D014644:Genetic Variation; D007700:Kinetics; D016296:Mutagenesis; D009154:Mutation / Q000502:physiology; D009251:NADPH-Ferrihemoprotein Reductase / Q000378:metabolism*; D010089:Oxidoreductases, N-Demethylating / Q000235:genetics* / Q000378:metabolism; D011110:Polymorphism, Genetic; D020122:tert-Butylhydroperoxide / Q000378:metabolism
chemical_list: D000480:Alkynes; D019380:Anti-HIV Agents; D018687:Antidepressive Agents, Second-Generation; D048588:Benzoxazines; D003374:Coumarins; D003521:Cyclopropanes; D005290:Ferric Compounds; D016642:Bupropion; C056033:7-ethoxy-4-trifluoromethylcoumarin; D020122:tert-Butylhydroperoxide; D001189:Aryl Hydrocarbon Hydroxylases; D065702:Cytochrome P-450 CYP2B6; D010089:Oxidoreductases, N-Demethylating; D009251:NADPH-Ferrihemoprotein Reductase; C098320:efavirenz